Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Theranexus    ALTHX   FR0013286259

THERANEXUS

(ALTHX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

THERANEXUS : announces its financial calendar for 2021

12/28/2020 | 12:25pm EDT

THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2021

Lyon, December 28, 2020 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announces its financial communication agenda for 2021. Each publication will be released after Euronext market closing, unless otherwise specified. This calendar of publication dates is for reference only, it is subject to change if necessary.

February 1st, 2021: Cash position as at December 31th 2020

April 7, 2021: 2020 Year-End Results and Cash position as at March 31th 2021

June 16, 2021: Annual Shareholders Meeting

July 8, 2021: Cash position as at June 30th 2021

September 30, 2021: 2021 Half-Year Results

October 19, 2021: Cash position as at September 30th 2021

Furthermore, Theranexus also planned to attend the following digital investor events : January 11-14,2021: JP Morgan Healthcare

January 26-27, 2021: Biomed Invest Securities Conference

February 10, 2021: CF&B Small and Midcap Event

ABOUT THERANEXUS

Theranexus is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Theranexus identified the key role played by non-neuronal cells (also known as "glial cells") in the body's response to psychotropic drugs (which target the neurons). The company is a pioneer in the design and development of drug candidates affecting the interaction between neurons and glial cells. The unique, patented technology used by Theranexus is designed to improve the efficacy of psychotropic drugs already approved and on the market, by combining them with a glial cell modulator. This strategy of combining its innovations with registered drugs means Theranexus can significantly reduce development time and costs and considerably increase the chance of its drugs reaching the market.

The proprietary, adaptable Theranexus platform can generate different proprietary drug candidates offering high added-value for multiple indications.

Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX). More information at: www.theranexus.com

More information on:

http://www.theranexus.com

Click and follow us on Twitter and Linkedln

Contacts

THERANEXUS

Thierry LAMBERT

ACTUS finance & communication

Financial and Administrative Director

Guillaume LE FLOCH

investisseurs@theranexus.fr

Investor Relations

+33 (0)1 53 67 36 70

theranexus@actus.fr

FP2COM

Florence PORTEJOIE

Media Relations

  • 33 (0)6 07 76 82 83 fportejoie@fp2com.fr

Disclaimer

Theranexus SA published this content on 28 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 December 2020 17:24:03 UTC


© Publicnow 2020
All news about THERANEXUS
04/07THERANEXUS  : 2020 full-year results and update on the progress of main programs
PU
04/07THERANEXUS  : 2020 full-year results and update on the progress of main programs
AN
04/07THERANEXUS  : Annual results
CO
03/10THERANEXUS  : Extends the capacities of neurolead, its asset screening platform,..
AQ
03/09THERANEXUS  : Theranexus extends the capabilities of neurolead, its active agent..
AN
01/22THERANEXUS  : presents an update on the progress of its main programs and announ..
PU
01/19THERANEXUS  : Provides an update on the progress of its main programs and announ..
AQ
01/18THERANEXUS  : Theranexus presents an update on the progress of its main programs..
AN
01/18THERANEXUS  : 4th quarter earnings
CO
2020THERANEXUS  : Publishes its 2021 financial agenda
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 -3,40 M -4,05 M -4,05 M
Net Debt 2020 - - -
P/E ratio 2020 -9,16x
Yield 2020 -
Capitalization 50,9 M 60,6 M 60,5 M
Capi. / Sales 2020 -
EV / Sales 2021 2,75x
Nbr of Employees 17
Free-Float 70,1%
Chart THERANEXUS
Duration : Period :
Theranexus Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERANEXUS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 25,50 €
Last Close Price 13,74 €
Spread / Highest target 162%
Spread / Average Target 85,6%
Spread / Lowest Target 45,6%
EPS Revisions
Managers and Directors
NameTitle
Franck Joseph Louis Mouthon Chairman & Chief Executive Officer
Thierry Bertrand Lambert Chief Financial & Administrative Officer
Mathieu Bernard Mari Charveriat Director, Chief Scientific Officer & Deputy CEO
Werner Rein Chief Medical Officer
Dominique Costantini Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
THERANEXUS-26.33%61
GILEAD SCIENCES, INC.11.76%81 411
VERTEX PHARMACEUTICALS INCORPORATED-9.62%55 284
WUXI APPTEC CO., LTD.-1.48%49 513
REGENERON PHARMACEUTICALS, INC.-1.64%49 239
BIONTECH SE49.07%29 350